STAT3 and AL amyloidosis: Interestingly, considering the mediating role of the JAK/STAT3 pathway in IL-6-induced muscle wasting, the role of the recently developed JAK and STAT3 inhibitors (i.e., ruxolitinib) on muscle mass and function should be further investigated especially when considering the significant benefit obtained specifically in ameliorating the cachectic symptoms in a large clinical trial in patients with multiple myeloma [132].